Squarepoint’s Palisade Bio PALI Stock Holding History
Bought
Maintained
Sold
Other funds holding PALI
BGI
OCA
PA
CC
RCM
EP
Squarepoint's PALI Position: Q1 2026 in Review
Squarepoint reduced its Palisade Bio (PALI) stake by 39% in Q1 2026, selling an estimated $228K and leaving 196,939 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #3603.
Squarepoint first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. The position peaked at $757K in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.
- Squarepoint held 196,939 shares of Palisade Bio worth $345K as of Q1 2026.
- Squarepoint sold 125,151 Palisade Bio shares in Q1 2026, an estimated $228K.
- Palisade Bio made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3603 holding.
- Squarepoint first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
- Squarepoint's Palisade Bio position peaked at $757K in Q4 2025.
- 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.